GE HealthCare Technologies Stock

$75.13

1.79% day before yesterday

Nasdaq, Jul 11, 10:07 pm CET

ISIN

US36266G1076

Symbol

GEHC

Reports

Quarter | Annual

Index

NASDAQ-100, S&P 500

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

GE HealthCare Technologies Stock price

$75.13

+15.13 25.22% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-1.37 1.79%

ISIN

US36266G1076

Symbol

GEHC

Reports

Quarter | Annual

Index

NASDAQ-100, S&P 500

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$34.4b

Enterprise Value

$40.7b

Net debt

$6.3b

Cash

$2.5b

Shares outstanding

457.8m

Valuation (TTM | estimate)

P/E

15.8 | 18.1

P/S

1.7 | 1.7

EV/Sales

2.1 | 2.0

EV/FCF

29.7

P/B

3.7

Dividends

DPS

$0.12

Yield 1Y | 5Y

0.2% | 0.1%

Growth 1Y | 5Y

33.3% | -

Payout 1Y | 3Y

2.8% | 1.8%

Increased

2 Years

Financials (TTM | estimate)

Revenue

$19.8b | $20.7b

EBITDA

$3.3b | $3.5b

EBIT

$2.7b | $2.9b

Net Income

$2.2b | $1.9b

Free Cash Flow

$1.4b

Growth (TTM | estimate)

Revenue

1.6% | 5.2%

EBITDA

8.8% | 8.6%

EBIT

12.3% | 10.7%

Net Income

39.0% | -4.5%

Free Cash Flow

-17.4%

Financial Health

Equity Ratio

25.5%

Return on Equity

23.6%

ROCE

11.5%

ROIC

8.9%

Debt/Equity

1.0

EPS

$4.8

FCF per Share

$3.0

Short interest

1.8%

Employees

51k

Rev per Employee

$390.0k

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

GE HealthCare Technologies Stock Analysis

Unlock Scores for Free

26 Analysts have issued a GE HealthCare Technologies forecast:

19x Buy

73%

7x Hold

27%

More details on Analyst Estimates Including Price Targets

26 Analysts have issued a GE HealthCare Technologies forecast:

Buy

73%

Hold

27%

Analyst Estimates with Stock Price Targets

Financial data from GE HealthCare Technologies

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	19,798 19,798	2% 2% 100%
- Direct Costs	11,484 11,484	1% 1% 58%
Gross Profit	8,314 8,314	5% 5% 42%
- Selling and Administrative Expenses	4,271 4,271	0% 0% 22%
- Research and Development Expense	1,331 1,331	6% 6% 7%
EBITDA	3,282 3,282	9% 9% 17%
- Depreciation and Amortization	568 568	5% 5% 3%
EBIT (Operating Income) EBIT	2,714 2,714	12% 12% 14%
Net Profit	2,183 2,183	39% 39% 11%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

GE HealthCare Technologies Stock News

Neutral

Business Wire

●

6 days ago

GE HealthCare to announce second quarter 2025 results on July 30, 2025

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news...

Neutral

Business Wire

●

12 days ago

GE HealthCare announces cash dividend for second quarter of 2025

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2025 payable on August 15, 2025 to all shareholders of record as of July 25, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider,...

Neutral

Business Wire

●

18 days ago

FDA Approves Expanded Indications for GE HealthCare's Vizamyl PET Imaging Agent for Beta Amyloid Detection, Enabling More Precise Care for Alzheimer's Patients

ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)--FDA approves expanded indications for GE HealthCare's Vizamyl PET imaging agent for beta amyloid detection, enabling more precise care for Alzheimer's.

More GE HealthCare Technologies News

Company Profile

GE Healthcare Technologies, Inc. operates as a holding company with interest in providing medical technology, pharmaceutical diagnostics and digital solutions. Its operating segments include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded on May 16, 2022 and is headquartered in Chicago, IL.

Head office	United States
CEO	Peter Arduini
Employees	51,000
Founded	2022
Website	www.gehealthcare.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now